中国银河证券股份有限公司 关于国新健康保障服务集团股份有限公司子公司股权变更暨部 分募投项目实施主体股权结构发生变化的核查意见 中国银河证券股份有限公司（以下简称"保荐人"）作为国新健康保障服务 集团股份有限公司（以下简称"国新健康"或"公司"）2022 年向特定对象发行 股票并在主板上市的保荐人，根据《证券发行上市保荐业务管理办法》《深圳证 券交易所股票上市规则》《深圳证券交易所上市公司自律监管指引第 1 号——主 板上市公司规范运作》等有关法规和规范性文件的要求，对国新健康子公司股权 变更暨部分募投项目实施主体股权结构发生变化的事项进行了核查，具体核查情 况如下： 一、子公司股权变更情况概述 为了进一步优化国新健康内部管理架构，压缩管理层级，提高管理效率，国 新健康全资子公司海南海虹投资咨询有限公司（以下简称"海南海虹"）拟通过 无偿划转方式将持有的北京海协智康科技发展有限公司（以下简称"北京海协"） 100%股权划转至国新健康。本次股权变更系公司及公司全资子公司的内部股权 结构调整，不影响公司合并报表范围和对子公司的持股权益。 北京海协、海南海虹均为公司全资子公司，本次交易不构成关联交易，亦不 构成《上 ...

证券简称：国新健康 证券代码：000503 编号：2025-74 国新健康保障服务集团股份有限公司 关于北京海协股权变更暨部分募投项目实施主体股权结构发生 变化的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、子公司股权变更情况概述 北京海协、海南海虹均为公司全资子公司，本次交易不构成关联交易，亦不 构成《上市公司重大资产重组管理办法》规定的重大资产重组。根据《深圳证券 交易所股票上市规则》等有关规定，上述交易已经公司第十二届董事会第八次会 议审议通过，无需提交公司股东会审议。 二、本次部分募投项目实施主体股权结构发生变化的情况 （一）部分募投项目实施主体股权结构变化情况概述 本次股权划转完成后，北京海协作为公司募投项目"营销网络升级建设项目" 的实施主体之一，股权结构发生变化，由公司直接持有北京海协100%股权，仍 将纳入本公司的合并报表范围。 上述募投项目实施主体北京海协的股权结构变更情况具体如下： | 募投项目名 | 募投项目 | 股权划出 | 股权划入方 | 变更前股权结 | 变更后股 | | --- | --- | --- | --- | ...

证券简称：国新健康 证券代码：000503 编号：2025-75 域创香港、益虹医通均为公司全资子公司，本次股权转让事项不构成关联交 易，亦不构成《上市公司重大资产重组管理办法》规定的重大资产重组。上述交 易已经公司第十二届董事会第八次会议审议通过，无需提交公司股东会审议。 二、股权转让方基本情况 1、企业名称：域创投资（香港）有限公司 一、本次股权转让情况概述 2、企业性质：私人股份有限公司 为了进一步优化公司内部管理架构，压缩管理层级，提高管理效率，国新健 康保障服务集团股份有限公司（以下简称"公司"或"国新健康"）全资子公司 域创投资（香港）有限公司（以下简称"域创香港"）拟通过非公开协议方式将 持有的北京益虹医通技术服务有限公司（以下简称"益虹医通"）100%股权转 让至国新健康，交易对价为345,523,290.56元。本次转让完成后，公司将直接持 有益虹医通100%股权。本次子公司股权变更系公司及公司全资子公司的内部股 权结构调整，不影响公司合并报表范围和对子公司的持股权益。 3、注册地址：UNIT B 10/F NATHAN COMM BLDG 430-436 NATHAN RD YAUMATI ...

证券简称：国新健康 证券代码：000503 编号：2025-72 国新健康保障服务集团股份有限公司 第十二届董事会第八次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 国新健康保障服务集团股份有限公司（以下简称"公司"）第十二届董事 会第八次会议于2025年11月18日发出会议通知，会议由董事长李永华先生召集 并主持，于2025年11月21日以现场结合通讯方式召开。本次会议应出席董事9人， 实际出席董事9人，公司高级管理人员列席会议。会议的召开符合有关法律、行 政法规、部门规章和《公司章程》规定。 本次会议以记名投票方式表决，审议通过了以下议案： 一、关于全资子公司股权内部无偿划转的议案 同意公司全资子公司国新健康保障服务有限公司通过无偿划转方式将持有 的国新健康保障服务（广东）有限公司100%股权划转至公司；公司全资子公司 海南海虹投资咨询有限公司通过无偿划转方式将持有的海南卫虹医药电子商务 有限公司80%股份划转至公司。 表决情况：9票赞成、0票反对、0票弃权。 具体内容详见同日在《中国证券报》《上海证券报》《证券时报》及巨潮 资讯网（网址： ...

Core Viewpoint - The company is transferring 100% equity of Beijing Yihong Medical Technology Service Co., Ltd. to itself through a non-public agreement for a transaction price of 346 million yuan, indicating an internal restructuring of equity [1] Group 1 - The subsidiary Yu Chuang Investment (Hong Kong) Co., Ltd. is involved in the equity transfer [1] - After the transfer, the company will directly hold 100% equity of Yihong Medical [1] - The transaction is part of the company's internal equity structure adjustment [1]

Market Overview - The medical consumables supply chain SPD sector experienced a decline of 1.42% on November 19, with Ailong Technology leading the drop [1] - The Shanghai Composite Index closed at 3946.74, up 0.18%, while the Shenzhen Component Index closed at 13080.09, unchanged [1] Stock Performance - Key stocks in the medical consumables supply chain SPD sector showed mixed performance, with Jianfa Zhixin rising by 3.19% to a closing price of 34.00, while several others, including Guoyao Yici and Jiuzhoutong, saw declines of 0.55% and 0.59% respectively [1] - The trading volume and turnover for Jianfa Zhixin were 180,800 hands and 620 million yuan, respectively [1] Capital Flow - The medical consumables supply chain SPD sector saw a net outflow of 99.05 million yuan from main funds, while retail investors contributed a net inflow of 74.72 million yuan [2] - Notable individual stock capital flows included Jianfa Zhixin with a net inflow of 70.39 million yuan from main funds, while Ailong Technology experienced a net outflow of 2.99 million yuan [3]

Core Insights - China Guoxin is enhancing its core functions as a state-owned capital operation company, focusing on supporting national strategies through diversified investment tools and financial services [1][6][7] Investment Strategy - Guoxin Fund has invested over 59 billion yuan in strategic emerging industries, achieving full coverage of nine strategic emerging industries and over 220 projects [2][3] - The fund emphasizes early, small, hard, and long-term investments, targeting original technology sources and supporting the development of a modern industrial system [2][3] Capital Deployment - Guoxin Investment has adopted a concentrated investment model, focusing on strategic emerging industries, with over 40 billion yuan allocated to key central enterprises [3][4] - The investment in strategic emerging industries accounts for nearly 80% of Guoxin Investment's total investments, enhancing state capital's control in critical sectors [3] Financial Services - Guoxin Securities has developed a specialized service model for central enterprises, covering 55 enterprises and maintaining a financing scale of over 30% of its total service [5] - The company is actively involved in issuing bonds and supporting green and technology innovation bonds, contributing significantly to the capital market [7] Ecosystem Development - Guoxin is building a "technology-industry-finance" cycle, enhancing the multiplier effect of state capital on the industrial chain [4][6] - The company is innovating in health and data services, developing platforms for drug traceability and digital identity verification [6] Strategic Partnerships - Guoxin Development has invested over 140 billion yuan to support 29 central enterprises, focusing on strategic projects and innovative investment patterns [4] - The company collaborates with local governments to establish funds targeting early-stage hard technology projects [2][4]

Core Viewpoint - The company has approved an associated transaction with China Guoxin, involving a contract worth RMB 2,840,000 for the development of a legal compliance system for equity investment [2][6][21]. Group 1: Meeting and Decision - The 7th meeting of the 12th Board of Directors was held on November 10, 2025, with all 9 directors present, and the meeting complied with legal and regulatory requirements [1][4]. - The proposal regarding the associated transaction with China Guoxin was approved with 5 votes in favor, 0 against, and 0 abstentions, with certain directors abstaining from voting due to conflicts of interest [2][8]. Group 2: Transaction Details - The contract involves the development of the "China Guoxin Equity Investment Legal Compliance Intelligent Review System" by the company's wholly-owned subsidiary, Guoxin Health Service Co., Ltd. [5][17]. - The total contract amount is RMB 2,840,000, which will be paid in installments based on project milestones and acceptance [18][21]. Group 3: Related Party Information - China Guoxin is the actual controller of the company and is classified as a related party under relevant regulations [7][15]. - The cumulative amount of transactions with China Guoxin over the past twelve months has reached RMB 4.434 million, meeting the disclosure standards for board review [23]. Group 4: Independent Directors' Opinion - The independent directors unanimously agreed that the associated transaction aligns with the company's operational needs, is reasonably priced, and does not significantly impact the company's independence or harm the interests of minority shareholders [21][22].

Core Points - Guoxin Health announced the approval of a related party transaction with China Guoxin, involving the construction of a legal compliance intelligent review system for equity investment [2] - The contract amount for the project is RMB 2,840,000, which includes tax [2] - The transaction is classified as a related party transaction since China Guoxin is the actual controller of the company [2]

格隆汇11月10日丨国新健康(000503.SZ)公布，公司全资子公司国新健康保障服务有限公司（简称"国新 健康有限"）与中国国新控股有限责任公司（简称"中国国新"）拟签署《中国国新股权投资法律合规智 能审查系统建设服务合同》，由国新健康有限为中国国新建设"中国国新股权投资法律合规智能审查系 统"，负责完成应用软件的设计开发、移交、培训及相关其他服务工作，合同金额（含税价）为人民币 2,840,000元。 ...